AVBP vs. OLMA, IGMS, PHAT, GHRS, AVTE, CALT, STTK, OCS, CDMO, and APLT
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Olema Pharmaceuticals (OLMA), IGM Biosciences (IGMS), Phathom Pharmaceuticals (PHAT), GH Research (GHRS), Aerovate Therapeutics (AVTE), Calliditas Therapeutics AB (publ) (CALT), Shattuck Labs (STTK), Oculis (OCS), Avid Bioservices (CDMO), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Olema Pharmaceuticals' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 23.5% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Olema Pharmaceuticals had 11 more articles in the media than ArriVent BioPharma. MarketBeat recorded 25 mentions for Olema Pharmaceuticals and 14 mentions for ArriVent BioPharma. Olema Pharmaceuticals' average media sentiment score of 1.23 beat ArriVent BioPharma's score of 0.64 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
Olema Pharmaceuticals received 16 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 60.53% of users gave Olema Pharmaceuticals an outperform vote.
Olema Pharmaceuticals currently has a consensus target price of $21.67, indicating a potential upside of 113.04%. ArriVent BioPharma has a consensus target price of $29.25, indicating a potential upside of 58.45%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than ArriVent BioPharma.
Summary
Olema Pharmaceuticals beats ArriVent BioPharma on 6 of the 11 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
